Events in our system are self-managed.  Group and event managers are encouraged to review privacy and security settings, and adjust them if needed.  If you need assistance please contact Indico Support - contact Help at bottom of page.

Apr 1 – 5, 2019
Fairmont Château Laurier Hotel
UTC timezone

Depleting the latent HIV-1 cell population using 225Ac-labeled anti-CD4+ targeted radioimmunoconjugates

Not scheduled
Fairmont Château Laurier Hotel

Fairmont Château Laurier Hotel


Dr Kris Barreto (University of Saskatchewan)


Barreto K1, Causey P2, Solomon VR3, Bernhard W1, Sutherland A1, Wilson JJ4, Geyer CR1, Sadowski I5, Fonge H3,6. 1Department of Pathology and Laboratory Medicine, University of Saskatchewan 2Canadian Nuclear Lab, Chalk River, ON 3Department of Medical Imaging, University of Saskatchewan 4Department of Chemistry & Chemical Biology, Cornell University 5Department of Biochemistry and Molecular Biology, University of British Columbia 6Department of Medical Imaging, Royal University Hospital Saskatoon **Overview:** A cure for HIV-1 has been elusive. Antiretroviral therapies eliminate the circulating viral load, but upon cessation of treatment the viral load rebounds from latent reservoirs. The Berlin patient is the only known patient cured of HIV-1 and underwent an aggressive ablation/transplant strategy where all T-cells were purged and replaced with T-cells resistant to infection. We present a targeted ablation strategy using a radioimmunotherapy (RIT). Anti-CD4 antibodies ibalizumab, recently FDA approved, and zanolimumab with a significant clinical track record are conjugated to an eight-membered macrocyclic chelator SCN-macropa, and then complexed with Actinum-225 to obtain 225Ac-ibalizumab or 225Ac-zanolimumab that specifically targets CD4+ T-cells. This RIT will be used to treat patient blood ex vivo. The amount of latent HIV in treated versus non-treated samples is compared. The objective of this research is to eliminate the latently infected HIV population. **Research methodology & results:** SCN-macropa has been synthesized. Anti-CD4 antibodies zanolimumab and ibalizumab were obtained from a commercial source and found to be 93% and 74% pure respectively. Flow cytometry was used to determine their affinity for CD4+ cells isolated from PBMCs as 420 ± 60 pM and 520 ± 20 pM respectively. Conjugation with SCN-macropa resulted in constructs with purities of 83% and 95% and similar binding constants of 400 pM and 200 pM to CD4+ cells isolated from PBMCs. In vitro experiments will be performed using live-cell imaging to determine specific cell killing of CD4+ versus CD4- cells. Depletion on CD4+ cells in PBMCs will be measured using flow cytometry and the amount of HIV DNA in patient blood samples before and after treatment will be quantified by specifically amplifying and quantifying the amount of proviral HIV DNA using real-time PCR. **Significance:** HIV-1 hides from treatment in resting immune cells, which means treatment must continue indefinitely. This preliminary study will allow us to determine if we can reduce or eliminate cells harboring latent HIV from patients’ blood sample using 225Ac-ibalizumab or 225Ac-zanolimumab. Combined with other therapies this strategy could result in a cure for HIV-1.
Funding Agency CIHR
Email Address
Presentation Type Poster

Primary author

Dr Kris Barreto (University of Saskatchewan)

Presentation materials

There are no materials yet.